CD8A and neoplasm: Hence, we here investigate application-relevant factors of VSV-GP, including the virus’ dose, route of immunization, presence of an antigen-positive tumor entity, and combination with a heterologous vaccine partner in regard to CD8+ T cell quantity and quality.